Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters

Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters

Marcin Pasiarski,1,2 Barbara Sosnowska-Pasiarska,3 Ewelina Grywalska,4,5 Agnieszka Stelmach-Gołdyś,1 Artur Kowalik,6 Stanisław Góźdź,2,7 Jacek Roliński4,5 1Department of Hematology, Holycross Cancer Center, Kielce, Poland; 2Department of Immunology, Faculty of Health Sciences, Jan Kochano...

Full description

Bibliographic Details
Main Authors: Pasiarski M, Sosnowska-Pasiarska B, Grywalska E, Stelmach-Gołdyś A, Kowalik A, Góźdź S, Roliński J
Format: Article
Language:English
Published: Dove Medical Press 2019-10-01
Series:Clinical Interventions in Aging
Subjects:
13-valent pneumococcal conjugate vaccine
immune response
monoclonal gammopathy of undetermined significance
M protein
plasmablasts
pneumococcal antibodies
Online Access:https://www.dovepress.com/immunogenicity-and-safety-of-the-13-valent-pneumococcal-conjugate-vacc-peer-reviewed-article-CIA

Internet

https://www.dovepress.com/immunogenicity-and-safety-of-the-13-valent-pneumococcal-conjugate-vacc-peer-reviewed-article-CIA

Similar Items